Neoadjuvant Nivolumab and Chemotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Retrospective Study

BACKGROUND: Patients with locally advanced (stage III) non-small cell lung cancer (NSCLC) demonstrate broad anatomic heterogeneity with modest survival benefits. Immune checkpoint inhibitors (ICIs) have shown survival benefit in metastatic NSCLC. We conducted this study to evaluate the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhai, Hengyu, Li, Wenhai, Jiang, Kun, Zhi, Yanan, Yang, Zhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841324/
https://www.ncbi.nlm.nih.gov/pubmed/35173485
http://dx.doi.org/10.2147/CMAR.S344343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841324/
https://www.ncbi.nlm.nih.gov/pubmed/35173485
http://dx.doi.org/10.2147/CMAR.S344343

Ejemplares similares